Press Release FeedGet the RSS feed
Menu

Business Wire

OneLegacy Celebrates the Career and Contributions of Medical Director Dr. Gabriel Danovitch, the 2026 Recipient of the Medawar Prize

Business Wire

OneLegacy Medical Director receives the world's highest dedicated honor in transplantation as he concludes over two decades of service to the organization.

AZUSA, Calif., August 25, 2026--OneLegacy, the nonprofit organ, eye, and tissue procurement organization serving seven counties across Southern California, celebrates the extraordinary career and contributions of Dr. Gabriel Danovitch, who is retiring from his role as Medical Director after over two decades with OneLegacy, while simultaneously receiving one of the most prestigious honors of his career: The Transplantation Society's 2026 Medawar Prize.

Recognized by The Transplantation Society as the world's highest dedicated award for outstanding contributions in the field of transplantation, the Medawar Prize honors investigators whose work has had a profound influence on organ transplantation worldwide. Established in honor of Society co-founder Sir Peter Medawar, the prize has been awarded biennially since 1990 to some of the most influential figures in transplant medicine and science.

For OneLegacy, Dr. Danovitch's recognition also celebrates the exceptional medical leadership he has brought to the organization and the Southern California donation and transplantation community as Medical Director.

"Dr. Danovitch's extraordinary career represents the very highest standard of transplant medicine, and OneLegacy has been privileged to flourish under his expertise, leadership, and commitment to patients and donor families," said Prasad Garimella, CEO of OneLegacy. "Receiving the Medawar Prize is a remarkable and well-deserved recognition of his contributions to transplantation around the world. As he concludes his service as OneLegacy's Medical Director, we celebrate not only this extraordinary honor, but the lasting impact his leadership has had on our organization and our ability to save and heal lives."

As OneLegacy's Medical Director and a contributing Advisory Board member for more than twenty years, Dr. Danovitch has both directly and indirectly contributed to many organizational accomplishments. During his tenure, OneLegacy opened both the Redlands Transplant and Recovery Center and the Azusa Transplant and Recovery Center. These facilities introduced the medical community to in-house recoveries at organ procurement organizations, which has now become the gold standard of organ recovery.

During his time at OneLegacy, Dr. Danovitch brought international expertise to the organization's work to advance organ donation, improve clinical practice, and increase the number of organs available for lifesaving transplantation. The esteemed nephrologist participated in thousands of cases, resulting in 8,954 donors recovered, 25,499 organs transplanted, and an 81% transplantation rate at OneLegacy during his tenure as medical director.

  1. Biotech & pharmaPfizer Inc.Pfizer's 25-Valent Pediatric Pneumococcal Conjugate Vaccine Candidate Shows Robust Phase 2 Data at IDWeek 2026Companies: PfizerInvestigational vaccine shows strong immune responses in infants equivalent to PREVNAR 20 ® on shared serotypes and for five new serotypes, potentially offering the broadest protection against invasive pneumococcal disease (IPD) for pediatric population in the U.S. NEW YORK, October 24, 2026--Pfizer I
  2. Biotech & pharmaIMFINZI® (durvalumab) plus tarlatamab-dlle reduced the risk of death by 58% in 1st-line extensive-stage small cell lung cancer in the DeLLphi-305 Phase III trialNovel combination demonstrated a median overall survival of nearly two years, the longest benefit ever reported in extensive stage disease in a Phase III trial Results reinforce IMFINZI as the backbone immunotherapy across stages of small cell lung cancer WILMINGTON, Del., October 24, 2026--Landmark re
  3. AutomotivePerioperative IMFINZI® (durvalumab) plus neoadjuvant enfortumab vedotin reduced risk of recurrence by 49% and risk of death by 42% in muscle-invasive bladder cancerMore than three quarters of patients were still alive two years after treatment with perioperative IMFINZI plus three cycles of EV given before surgery Data demonstrated statistically significant and clinically meaningful survival benefit and manageable safety profile WILMINGTON, Del., October 24, 2026 --
  4. ESMO 2026: NUBEQA® (darolutamide) Plus ADT and Radiation Therapy Reduces Risk of Metastasis or Death by 58% in Prostate Cancer Patients at High Risk of RecurrenceInterim analysis results from the Phase III DASL-HiCaP trial show a statistically significant 58% reduction in the risk of metastasis or death with NUBEQA® (darolutamide) versus placebo in addition to androgen deprivation therapy (ADT) and radiation therapy (hazard ratio [HR] 0.42; 95% CI: 0.27–0.66; p=0.0001) Four-year m
  5. FinanceSemtech CorporationSemtech Brings 5G Network Slicing, FIPS 140-3 to IACP 2026AirLink 5G Solutions Keep First Responders Connected During Peak Network Demand CAMARILLO, Calif., October 24, 2026--Semtech Corporation (Nasdaq: SMTC), a leading provider of high-performance semiconductors powering AI data center networking and intelligent, connected Internet of Things ("IoT") devices
  6. FinanceGenmab A/SGenmab and Incyte Announce Clinical Trial Collaboration in Metastatic Colorectal CancerCompanies: IncytePhase 1/2 study will evaluate petosemtamab plus INCB161734 and standard-of-care chemotherapy in first-line KRAS G12D-mutated metastatic colorectal cancer (mCRC) COPENHAGEN, Denmark & WILMINGTON, Del., October 24, 2026--Genmab A/S (Nasdaq: GMAB) and Incyte (Nasdaq: INCY) today announced a clinical tria